PresentationSo with that, maybe before we dive deep into the pipeline, I believe you recently announced new board appointments yesterday, the latest in several new appointments this year. So maybe before we start, could you talk a bit more about the appointments and what significant -- how they're significant for Bicycle?Hello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm happy to welcome Bicycle Therapeutics, specifically Kevin Lee, CEO; Alethia Young, CFO; and Jennifer Perry, Chi ...